A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today announced updated clinical ...